Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China
CONCLUSION: Addition of Evolocumab to the standard double therapy in Chinese CHD patients improved the efficacy in LDL-C reduction when compared to Rosuvastatin alone or in Rosuvastatin/Ezetimibe double therapy. Furthermore, the addition of Evolocumab lowered LP(a) level in Chinese CHD patients.PMID:34375677 | DOI:10.1016/j.trim.2021.101444
Source: Transplant Immunology - Category: Transplant Surgery Authors: Yi Liu Bing Han Source Type: research
More News: Allergy & Immunology | Cardiology | China Health | Cholesterol | Coronary Heart Disease | Crestor | Heart | Heart Disease | Heart Transplant | Japan Health | Rosuvastatin | Statin Therapy | Statistics | Study | Transplant Surgery | Transplants | Vytorin | Zetia